Sign in

Ben Teh

@benwteh.bsky.social
307 followers 87 following 16 posts

ID physician & Clinician researcher @petermaccc.bsky.social #TxID #Haem #Vaccination

PostsRepliesMedia
Ben Teh @benwteh.bsky.social · 29/09/2026
Great work by superstar Gemma Reynolds. Early steps towards personalising infection management in CAR-T patients. Collab between @petermaccc.bsky.social @wehi-research.bsky.social @ncicancer.bsky.social www.journalofinfection.com/article/S016...
journalofinfection.com
Host immune biomarkers associated with infection risk after CAR T-cell therapy
Infection is the leading cause of non-relapse mortality after CAR-T therapy, yet individual risk prediction remains challenging. This exploratory study evaluated immune correlates of infection and oth...
000
Ben Teh @benwteh.bsky.social · 29/07/2026
Great work by our ID fellow. RSV schedules, CAR-T and immune markers are research priorities @ncicancer.bsky.social @theebmt.bsky.social url.au.m.mimecastprotect.com/s/S-prCNLwzj...
url.au.m.mimecastprotect.com
Vaccination in haematopoietic stem cell transplantation and cellular therapies: consensus, divergence, and uncertainties in global practice
Bone Marrow Transplantation - Vaccination in haematopoietic stem cell transplantation and cellular therapies: consensus, divergence, and uncertainties in global practice
021
Reposted by Ben Teh
International Immunocompromised Host Society @ichs-global.bsky.social · 20/11/2025
Please participate in a brief survey, your insights are invaluable in helping to understand current practices, identify areas of variation, and inform future guidelines. redcap.petermac.org.au/surveys/?s=P...
011
Reposted by Ben Teh
asidaud.bsky.social @asidaud.bsky.social · 08/09/2025
Challenging CMV Cases in Solid Organ Transplant Recipients Wednesday 15 October 2025 6.00pm - 7.30pm Presenters: Helen Tang (RPAH) Jenny Li (Alfred) Becky Lane (ADHB) To register click asidevents.eventsair.com/cmv-webinars....
asidevents.eventsair.com
CMV #2 Webinar
001
Reposted by Ben Teh
asidaud.bsky.social @asidaud.bsky.social · 08/09/2025
ASID is hosting two webinars on CMV thanks to the support of Takeda Educational Grant. Challenging CMV Cases in Hematologic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies Wednesday 17 September 6.00pm - 7.30pm To register - asidevents.eventsair.com/cmv-webinars...
asidevents.eventsair.com
CMV #1 Webinar Registration
101
Reposted by Ben Teh
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 12/08/2025
Paper 2-Innovation in active and passive immunisation of people who are immunocompromised: a call to action www.thelancet.com/journals/lan...
thelancet.com
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
The proportion of the population with immunocompromising conditions, who are at increased risk for complications from infectious diseases, continues to grow. Concurrently, outbreaks due to known and e...
111
Ben Teh @benwteh.bsky.social · 12/08/2025
More critical than ever - @ncicancer.bsky.social @petermaccc.bsky.social #TxID Innovation in active and passive immunisation of people who are immunocompromised: a call to action - The Lancet Infectious Diseases www.thelancet.com/journals/lan...
thelancet.com
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
The proportion of the population with immunocompromising conditions, who are at increased risk for complications from infectious diseases, continues to grow. Concurrently, outbreaks due to known and e...
020
Ben Teh @benwteh.bsky.social · 08/08/2025
Delighted to have been part of these important ECiL-10 c diff guidelines specific to our haematology patients. #TxID @ncicancer.bsky.social @ichs-global.bsky.social @theebmt.bsky.social www.sciencedirect.com/science/arti...
smex-ctp.trendmicro.com
ScienceDirect.com | Science, health and medical journals, full text articles and books.
121
Ben Teh @benwteh.bsky.social · 30/07/2025
Huge thanks to haem cancer consumers for guiding us on how to improve delivery of vaccination. Uptake is key! #TxID @ncicancer.bsky.social url.au.m.mimecastprotect.com/s/R9OxCK1qwB...
url.au.m.mimecastprotect.com
ScienceDirect.com | Science, health and medical journals, full text articles and books.
110
Ben Teh @benwteh.bsky.social · 04/07/2025
Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial url: academic.oup.com/jid/article-...
academic.oup.com
Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial
In an in-depth immunological analysis of alternate influenza vaccination strategies in high-risk patients receiving therapy for hematological malignancy, p
153
Ben Teh @benwteh.bsky.social · 02/05/2025
The national update on vaccination in immunocompromised is out! Delighted to have contributed to this. #TxID
immunisationhandbook.health.gov.au
030
Ben Teh @benwteh.bsky.social · 13/04/2025
It was very lovely of @joshhillmd.bsky.social to highlight our trial in his top 10 papers at #escmidglobal www.nejm.org/doi/abs/10.1...
120
Reposted by Ben Teh
NCICancer @ncicancer.bsky.social · 08/04/2025
We are excited for #ESCMIDGLOBAL - the premier event for Infectious Diseases and Microbiology hosted by @escmid.bsky.social in Vienna, Austria! 🌍 If you're planning to attend, we’d love to connect with you. Below are the details of our presentations, including titles, times, and locations.
243
Reposted by Ben Teh
Priya Garg @priyagargiddoc.bsky.social · 04/04/2025
Honoured to speak & present our @ncicancer.bsky.social work on infection prevention in cancer/transplant at the Australasian Society of ID ASM with @nikhil-singh.bsky.social @michyong.bsky.social @benwteh.bsky.social, & amazing to hear & see the incredible work done at other centres nationally 👏🏽
282
Reposted by Ben Teh
Michael G. Ison, MD MS @michaelisonmd.bsky.social · 17/03/2025
Vaccines are critical for the protection of patients from infection - it was an honor to write this piece discussing the challenges and data needs for use in immunocompromised patients. academic.oup.com/jid/article/...
academic.oup.com
Vaccines for Use in Special Populations: Immunocompromised Hosts
The proportion of immunocompromised individuals in the United States has grown rapidly and currently accounts for 6.6% of the US population [1]. Individual
0156
Reposted by Ben Teh
NCICancer @ncicancer.bsky.social · 18/02/2025
Join us at the 15th Febrile Neutropenia Symposium, taking place online on March 15–16, 2025! NCIC Researcher, @benwteh.bsky.social, will present on 'Standardised Reporting of Infection Events in Immunocompromised Patients.' To learn more and sign up: cdn.wildapricot.com/24830/resour...
131
Ben Teh @benwteh.bsky.social · 08/02/2025
What drives or discourages our haematology patients from getting vaccinated. Lovely collab with HSR team @petermaccc.bsky.social www.sciencedirect.com/science/arti... #TxID #HaemOncID
sciencedirect.com
“It's a risk-benefit analysis”: Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia
People affected by haematological malignancies are at high risk of morbidity and mortality caused by vaccine-preventable infections. However, vaccinat…
020
Reposted by Ben Teh
Michael G. Ison, MD MS @michaelisonmd.bsky.social · 06/02/2025
We need anyone interested in reviewing for the journal to use this survey to submit interest. This will help us better tailor papers we send to you for review! Even if you are already reviewing for us, would encourage you to submit your preference. #IDSky
0115
Reposted by Ben Teh
NEJM.org @nejm.org · 19/01/2025
In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines. Read the full trial results: nej.md/40ztLNF #MedSky #IDSky #Oncology
nej.md
Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM
In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.
02111
Reposted by Ben Teh
Tori Hall @victoriahall.bsky.social · 16/01/2025
Very proud of this hard work & team effort from all involved! Limited benefit of adjuvanted flu 💉 & 2 vs 1 dose in pts w/ MM, CLL or NHL. @ncicancer.bsky.social @petermaccc.bsky.social @benwteh.bsky.social @trubianojason.bsky.social @michyong.bsky.social @nejm.org www.nejm.org/doi/full/10....
nejm.org
Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM
In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.
295
Ben Teh @benwteh.bsky.social · 16/01/2025
Practice affirming results from our team @victoriahall.bsky.social @ncicancer.bsky.social - No additional benefit from second influenza vaccine dose/adjuvant vaccines in non-HCT haematology patients. #TxID #IDsky #medsky www.nejm.org/doi/full/10....
nejm.org
Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM
In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.
0177
Reposted by Ben Teh
Clinical Infectious Diseases @cidjournal.bsky.social · 23/12/2024
Glucocorticoid dosing and implications for vaccination: Evolution of global definitions ✅ Just Accepted #IDSky
buff.ly
Glucocorticoid dosing and implications for vaccination: Evolution of global definitions
Despite widespread adoption of “high-dose” glucocorticoid definitions across international immunisation guidelines (i.e., prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear. Literature searches were performed through academic databases for this narrative review to identify relevant evidence regarding glucocorticoid dosing on vaccine responses and safety.
0154